Role of interleukin‐4 and interleukin‐10 in murine collagen‐induced arthritis. Protective effect of interleukin‐4 and interleukin‐10 treatment on cartilage destruction
- 1 February 1997
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 40 (2) , 249-260
- https://doi.org/10.1002/art.1780400209
Abstract
To examine the role of endogenous interleukin-4 (IL-4) and interleukin-10 (IL-10) and the therapeutic effect of the addition of IL-4 and IL-10 in early and established murine collagen-induced arthritis (CIA). Murine recombinant IL-4, IL-10, or the combination was given intraperitoneally twice daily from the day of arthritis onset up to 7-10 days of CIA in DBA/1 mice. Anti-IL-4, anti-IL-10, or both antibodies were given intraperitoneally before or after the onset of CIA. The effect of cytokine or anticytokine treatment was monitored visually by macroscopic scoring. Histology and reverse transcription-polymerase chain reaction (RT-PCR) analyses were performed at the end of the treatment period. IL-4 alone did not provoke any effect, IL-10 slightly suppressed the arthritis, but a more pronounced amelioration was found with the combination. This cooperative effect was noted after early treatment but also occurred when the start of treatment was delayed until 1 week after onset. Apart from suppression of macroscopic signs of inflammation, combined treatment with IL-4/IL-10 also reduced cellular infiltrates in the synovial tissue and caused pronounced protection against cartilage destruction. Moreover, levels of mRNA for tumor necrosis factor alpha (TNF alpha) and IL-1 were highly suppressed both in the synovial tissue and in the articular cartilage. In contrast, levels of IL-1 receptor antagonist (IL-1Ra) mRNA remained elevated, which suggests that the mechanism of protection may be related to suppressed production of TNF alpha and IL-1, with concomitant up-regulation of the IL-1Ra/IL-1 balance. However, accelerated onset of CIA and increased severity could be achieved with neutralizing anti-IL-10 antibodies. This expression could be further optimized with a combination of anti-IL-4 and anti-IL-10 antibodies, although anti-IL-4 alone was without effect. Our data are consistent with a dominant role of IL-10 in the natural suppression of arthritis expression, whereas combined treatment with IL-4 and IL-10 appears of potential therapeutic value, not only at the onset, but also in established arthritis.Keywords
This publication has 51 references indexed in Scilit:
- Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulationImmunological Reviews, 2008
- Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.Journal of Clinical Investigation, 1995
- THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITISRheumatology, 1995
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- Elevated interleukin-10 levels in patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation.The Journal of Experimental Medicine, 1994
- Immunoregulatory role of interleukin 10 in rheumatoid arthritis.The Journal of Experimental Medicine, 1994
- Interleukin-1 Type II Receptor: A Decoy Target for IL-1 That Is Regulated by IL-4Science, 1993
- In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp‐lpr/lpr mouseEuropean Journal of Immunology, 1990
- Immunisation against heterologous type II collagen induces arthritis in miceNature, 1980